Physician profile
Kristen E Robillard
NPI 1144391889
$4,870.98
in general payments reported to CMS, 2019-2025
22 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $123 · 2021: $132 · 2022: $477 · 2023: $1,136 · 2024: $1,038 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347 · Education: $78.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,346.85 |
| Education | $78.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,299.85 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $759.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $474.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $464.27 | 2022-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $437.58 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $373.76 | 2019-2025 | |
| Amgen INC. | $260.07 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $230.49 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $114.04 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $74.42 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.63 | 2019-2022 | |
| Allergan, INC. | $51.99 | 2019 | |
| Verona Pharma, INC. | $50.24 | 2025 | Ohtuvayre |
| Insulet Corporation | $42.91 | 2025 | Omnipod |
| Paratek Pharmaceuticals, INC. | $38.59 | 2025 | Nuzyra, Xhance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34.85 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $19.48 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.73 | 2019 | |
| Ibsa Pharma INC. | $17.07 | 2024 | Tirosint, Licart |
| Idorsia Pharmaceuticals US INC | $15.08 | 2022 | |
| Seqirus USA INC | $14.59 | 2025 | Fluad, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Robillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.